Entera Bio (NASDAQ:ENTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Entera Bio (NASDAQ:ENTX) to a sell rating in a report issued on Saturday.

ENTX has been the subject of several other reports. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

Entera Bio Price Performance

Entera Bio stock opened at $3.04 on Friday. The stock has a market cap of $149.84 million, a price-to-earnings ratio of -8.69 and a beta of 1.37. The firm has a 50-day moving average of $1.88 and a two-hundred day moving average of $1.50. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Research analysts expect that Entera Bio will post -0.34 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

Institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP raised its stake in Entera Bio by 51.9% in the first quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after buying an additional 70,224 shares in the last quarter. Renaissance Technologies LLC boosted its position in Entera Bio by 338.4% during the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock valued at $526,000 after acquiring an additional 365,441 shares in the last quarter. Superstring Capital Management LP purchased a new position in shares of Entera Bio in the 4th quarter valued at $33,000. Schonfeld Strategic Advisors LLC increased its holdings in shares of Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after acquiring an additional 29,629 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares in the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.